AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Aug 8, 2024
30604_dirs_2024-08-08_9acc94c9-b8b1-42ba-9bc1-8aaa799a4f3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-08-06
Reporting Person: Trimarchi Thomas (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-06 | Common Stock | A | 19003 | — | Acquired | 413859 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-08-06 | Stock Option (Right to Buy) | $24.87 | A | 3160 | Acquired | 2034-08-05 | Common Stock (3160) | Direct |
Footnotes
F1: Grant of restricted stock units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The stock option shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.